Candidate Synthetic Lethality Partners to PARP Inhibitors in the Treatment of Ovarian Clear Cell Cancer (Review)

Biomedical Reports - Greece
doi 10.3892/br.2017.990
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

PARP Inhibitors in Ovarian Cancer

2013English

Extending the Scope of PARP Inhibitors in Ovarian Cancer

The Lancet Oncology
Oncology
2019English

The Development of PARP Inhibitors in Ovarian Cancer: From Bench to Bedside

British Journal of Cancer
Cancer ResearchOncology
2015English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer
Cancer ResearchOncology
2011English

PARP Inhibitors in Ovarian Cancer: Sensitivity Prediction and Resistance Mechanisms

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

PARP Inhibitors and Stratified Treatment of Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer

Cancer Research
Cancer ResearchOncology
2013English

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy